Prostamax
A synthetic tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson bioregulator family, studied for prostatic tissue bioregulation and geroprotective effects.
Also referenced as: KEDP, Lys-Glu-Asp-Pro
Also appears in: Longevity
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Other. Also surfaces under Longevity for browsing and discovery.
KEDP, Lys-Glu-Asp-Pro
No FDA label signal · 0 trials · 9 PubMed results
Current evidence for Prostamax is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Prostamax has no clinical trials that name it and 9 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Prostamax?
Prostamax is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Pro (KEDP), developed as part of Vladimir Khavinson’s bioregulator peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. It is classified as a prostate-tissue bioregulator within the Khavinson framework of organ-specific short peptides.
How it works
The proposed mechanism follows the Khavinson bioregulation model:
- Tissue-specific gene regulation — short peptides are theorized to penetrate cell nuclei and interact with gene promoter regions in a tissue-specific manner, modulating transcription of genes relevant to prostatic function (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Geroprotective effects — bioregulator peptide preparations targeting various organs have been associated with improved tissue function in aged animals and reduced age-related pathology (Khavinson, Gerontology, 2005)
Research status
- Khavinson (2005) reviewed 35 years of peptide bioregulator research including organ-specific peptides (Gerontology, 51(2):70–75)
- Khavinson & Malinin (2005) described the theoretical framework for tissue-specific short peptide bioregulation (Neuroendocrinology Letters, 26(3):233–238)
- Published clinical data specific to Prostamax is limited to Russian-language literature from the Khavinson group
Key considerations
- Part of the Khavinson bioregulator family alongside Pinealon, Cartalax, Epitalon, and others — same research group, same proposed mechanism, different target tissues
- No independent Western replication studies or peer-reviewed clinical trials
- Available from research vendors as lyophilized powder or capsules (typically 10–20mg)